Insulet/$PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Ticker
$PODD
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
3,900
Website
Insulet Metrics
BasicAdvanced
$20B
51.47
$5.55
1.35
-
Price and volume
Market cap
$20B
Beta
1.35
52-week high
$329.33
52-week low
$173.00
Average daily volume
728K
Financial strength
Current ratio
4.474
Quick ratio
3.239
Long term debt to equity
125.212
Total debt to equity
131.405
Interest coverage (TTM)
8.27%
Profitability
EBITDA (TTM)
423
Gross margin (TTM)
70.39%
Net profit margin (TTM)
18.29%
Operating margin (TTM)
15.50%
Effective tax rate (TTM)
-37.08%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
6.94%
Return on equity (TTM)
37.92%
Valuation
Price to earnings (TTM)
51.467
Price to revenue (TTM)
9.111
Price to book
15.08
Price to tangible book (TTM)
17.04
Price to free cash flow (TTM)
71.346
Free cash flow yield (TTM)
1.40%
Free cash flow per share (TTM)
400.26%
Growth
Revenue change (TTM)
23.49%
Earnings per share change (TTM)
67.46%
3-year revenue growth (CAGR)
24.41%
10-year revenue growth (CAGR)
23.44%
3-year earnings per share growth (CAGR)
105.59%
10-year earnings per share growth (CAGR)
18.44%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Bulls say / Bears say
Insulet's Omnipod 5 device is the first system to receive clearance for managing both type 1 and type 2 diabetes, expanding its market reach. (reuters.com)
The company reported a 28.8% increase in total revenue for Q1 2025, surpassing analyst estimates and indicating strong product demand. (reuters.com)
Insulet raised its full-year revenue growth guidance to between 19% and 22%, reflecting confidence in sustained growth. (reuters.com)
The U.S. Appeals Court removed a preliminary injunction against EOFlow, potentially increasing competition in the tubeless insulin pump market. (reuters.com)
Short-seller Blue Orca Capital revealed a short position in Insulet, citing concerns over the company's market position amid rising competition. (reuters.com)
Investor concerns persist regarding the impact of GLP-1 drugs on insulin pump demand, which could affect Insulet's future sales. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Insulet News
AllArticlesVideos
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
Business Wire·2 weeks ago
Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids
Investors Business Daily·3 weeks ago
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $20B as of July 24, 2025.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 51.47 as of July 24, 2025.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of July 24, 2025.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.